Atox Bio Revenue and Competitors

Location

$58.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Atox Bio's estimated annual revenue is currently $1.6M per year.(i)
  • Atox Bio's estimated revenue per employee is $77,500
  • Atox Bio's total funding is $58.4M.

Employee Data

  • Atox Bio has 21 Employees.(i)
  • Atox Bio grew their employee count by 91% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.9M8324%N/AN/A
#2
$5304.1M342202%N/AN/A
#3
$1.7M110%N/AN/A
#4
$1.4M9-61%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$2M130%N/AN/A
#7
$1.1M7-36%N/AN/A
#8
$6.2M408%N/AN/A
#9
$5.1M3314%N/AN/A
#10
$1.1M70%N/AN/A
Add Company

Atox Bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. Reltecimod (AB103) , the company?s lead product, is studied in ACCUTE (Reltecimod Clinical Composite endpoint Study in necrotizing soft Tissue InfEctions), a phase 3 clinical trial in patients with Necrotizing Soft Tissue Infections, a rare, life threatening infection for which no therapy currently exists. Reltecimod is also being studied in REAKT (Reltecimod Efficacy for Acute Kidney Injury Trial), a phase 2 study in patients with abdominal sepsis induced Acute Kidney Injury. Reltecimod received Orphan Drug designation from the FDA and EMA and Fast Track designation from the FDA.

keywords:N/A

$58.4M

Total Funding

21

Number of Employees

$1.6M

Revenue (est)

91%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Atox Bio News

2022-04-17 - T Cell Specific Surface Glycoprotein Cd28 Market Size 2022 ...

Atox Bio Ltd; Bristol-myers Squibb Co; Five Prime Therapeutics Inc; Johnson & Johnson; Theramab Llc … T Cell Specific Surface Glycoprotein Cd28...

2022-04-13 - Acute Kidney Injury Pipeline to Progress with Novel and Emerging Drugs for Treatment, Analyzes DelveInsight

The key players operating in the Acute Kidney Injury treatment market include Atox Bio, AM-Pharma, Angion Biomedica, Astellas Pharma,...

2017-12-04 - Atox Bio Closes $30M Funding Round

Atox Bio, a Ness Ziona, Israel and Chapel Hill, NC –based clinical stage biotechnology company developing novel therapies for critically ill patients, raised $30m in funding. The round was led by Arix Bioscience plc with participation from Adams Street Partners, Asahi Kasei Corporation and addi ...

2017-12-04 - Atox Bio clos­es $30M round as it speeds through late-stage tri­als

Is­rael’s Atox Bio has raised $30 mil­lion — the lat­est in a long line of eq­ui­ty deals — to help push its im­mune mod­u­la­tors through late-stage clin­i­cal tri­als. The com­pa­ny is work­ing on im­mune mod­u­la­tors for pa­tients with se­vere in­fec­tions and tis­sue in­jury. The com­pa­ny ...

2014-07-25 - Atox Bio Raises up to $23M in Series E Investment

Atox Bio, a Ness Ziona, Israel-based developer of therapeutics for severe infections, raised up to $23m in Series E investment. The round was led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel. The company intends to use the funds to initiate a late stage clinical stu ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M21N/AN/A
#2
$1.5M2140%N/A
#3
$2.1M21N/AN/A
#4
$2.4M23-26%N/A
#5
$2.2M249%N/A